Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information ("Second Request") from the United States Federal Trade Commission (FTC) in connection with the pending acquisition of CTP-656 and other assets
View HTML
Toggle Summary Concert Pharmaceuticals Announces Clinical Hold on CTP-543 Phase 2a Trial
-- FDA Requested Review of Recently Completed Non-Clinical Studies -- -- FDA Did Not Cite a Safety Concern -- LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its
View HTML
Toggle Summary Concert Pharmaceuticals Reports First Quarter 2017 Financial Results
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2017. "We expect to significantly strengthen our cash position in 2017 through the asset purchase agreement
View HTML
Toggle Summary Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles,
View HTML
Toggle Summary Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2017 financial results on Tuesday, May 2, 2017 , before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Year Ended 2016 Financial Results
- Vertex Pharmaceuticals to Acquire Cystic Fibrosis Candidate, CTP-656, from Concert Pharmaceuticals for up to $250 Million - - CTP-543 On Track to Advance Into Phase 2a Trial - - Conference Call Scheduled Today at 8:30 a.m. EST - LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
- Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF - - Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments - - Concert to Host Conference Call at 8:30 AM EST to
View HTML
Toggle Summary Concert Pharmaceuticals Presents CTP-543 Phase 1 Results at American Academy of Dermatology Annual Meeting
- Program on Track to Begin Phase 2a Trial in the First Quarter of 2017 - LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that the results from the Company's Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers
View HTML
Toggle Summary Concert Pharmaceuticals to Report Full Year 2016 Results on March 6, 2017, and Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2016 , on Monday, March 6, 2017 , before the U.S. financial markets open. The Company will host a conference call and webcast
View HTML
Toggle Summary Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for CTP-656, Concert's next generation CFTR potentiator being developed for the treatment of cystic fibrosis.
View HTML